These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 38130284)

  • 1. Initial Experiences in Adolescents and Young Adults with T-Cell Acute Lymphoblastic Leukemia/Lymphoma Treated with the Modified BFM 2002 Protocol in a Resource-Constrained Setting.
    Jinwala P; Patidar R; Bansal S; Asati V; Shrivastava SP; Elhence A; Patel S; Chitalkar PG
    South Asian J Cancer; 2023 Oct; 12(4):378-383. PubMed ID: 38130284
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nelarabine, intensive L-asparaginase, and protracted intrathecal therapy for newly diagnosed T-cell acute lymphoblastic leukaemia in children and young adults (ALL-T11): a nationwide, multicenter, phase 2 trial including randomisation in the very high-risk group.
    Sato A; Hatta Y; Imai C; Oshima K; Okamoto Y; Deguchi T; Hashii Y; Fukushima T; Hori T; Kiyokawa N; Kato M; Saito S; Anami K; Sakamoto T; Kosaka Y; Suenobu S; Imamura T; Kada A; Saito AM; Manabe A; Kiyoi H; Matsumura I; Koh K; Watanabe A; Miyazaki Y; Horibe K
    Lancet Haematol; 2023 Jun; 10(6):e419-e432. PubMed ID: 37167992
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early T-cell precursor acute lymphoblastic leukaemia in children treated in AIEOP centres with AIEOP-BFM protocols: a retrospective analysis.
    Conter V; Valsecchi MG; Buldini B; Parasole R; Locatelli F; Colombini A; Rizzari C; Putti MC; Barisone E; Lo Nigro L; Santoro N; Ziino O; Pession A; Testi AM; Micalizzi C; Casale F; Pierani P; Cesaro S; Cellini M; Silvestri D; Cazzaniga G; Biondi A; Basso G
    Lancet Haematol; 2016 Feb; 3(2):e80-6. PubMed ID: 26853647
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Poor outcome for children and adolescents with progressive disease or relapse of lymphoblastic lymphoma: a report from the berlin-frankfurt-muenster group.
    Burkhardt B; Reiter A; Landmann E; Lang P; Lassay L; Dickerhoff R; Lakomek M; Henze G; von Stackelberg A
    J Clin Oncol; 2009 Jul; 27(20):3363-9. PubMed ID: 19433688
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcomes of Philadelphia Positive Acute Lymphoblastic Leukemia in Adolescent and Young Adults.
    Ahmed U; Ahmed D; Awan MN; Ahmad U; Ahsan B; Iftikhar R; Mir MA; Bokhari SW
    Cureus; 2022 Dec; 14(12):e32467. PubMed ID: 36644079
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Minimal residual disease values discriminate between low and high relapse risk in children with B-cell precursor acute lymphoblastic leukemia and an intrachromosomal amplification of chromosome 21: the Austrian and German acute lymphoblastic leukemia Berlin-Frankfurt-Munster (ALL-BFM) trials.
    Attarbaschi A; Mann G; Panzer-Grümayer R; Röttgers S; Steiner M; König M; Csinady E; Dworzak MN; Seidel M; Janousek D; Möricke A; Reichelt C; Harbott J; Schrappe M; Gadner H; Haas OA
    J Clin Oncol; 2008 Jun; 26(18):3046-50. PubMed ID: 18565891
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intensive chemotherapy improved treatment outcome for Chinese children and adolescents with lymphoblastic lymphoma.
    Sun XF; Xia ZJ; Zhen ZJ; Xiang XJ; Xia Y; Ling JY; Liu DG; Huang HQ; Zhen L; Luo WB; Lin H; Guan ZZ
    Int J Clin Oncol; 2008 Oct; 13(5):436-41. PubMed ID: 18946754
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical outcomes and prognostic factors in children with B-cell lymphoblastic lymphoma (LBL) treated according to on modified BFM-90 protocol: Experience from a Tertiary cancer care center in India.
    Vijayasekharan K; Kc A; Prasad M; Dhamne C; Roy Moulik N; Shet T; Sridhar E; Laskar S; Kembhavi S; Shah S; Gujral S; Narula G; Banavali SD
    Pediatr Hematol Oncol; 2022 Aug; 39(5):427-440. PubMed ID: 35179438
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcomes and prognostic factors in adolescents and young adults with ALL treated with a modified BFM-90 protocol.
    Rajendra A; Jain H; Bonda VNA; Nayak L; Tembhare P; Shetty D; Thorat J; Jain H; Subramanian PG; Patkar N; Chatterjee G; Khattry N; Gokarn A; Punatar S; Mokal S; Bagal B; Sengar M
    Blood Adv; 2021 Mar; 5(5):1178-1193. PubMed ID: 33635331
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of patients with acute lymphoblastic leukemia with bulky extramedullary disease and T-cell phenotype or other poor prognostic features: randomized controlled trial from the Children's Cancer Group.
    Steinherz PG; Gaynon PS; Breneman JC; Cherlow JM; Grossman NJ; Kersey JH; Johnstone HS; Sather HN; Trigg ME; Uckun FM; Bleyer WA
    Cancer; 1998 Feb; 82(3):600-12. PubMed ID: 9452280
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical utility of miR-143/miR-182 levels in prognosis and risk stratification specificity of BFM-treated childhood acute lymphoblastic leukemia.
    Piatopoulou D; Avgeris M; Drakaki I; Marmarinos A; Xagorari M; Baka M; Pourtsidis A; Kossiva L; Gourgiotis D; Scorilas A
    Ann Hematol; 2018 Jul; 97(7):1169-1182. PubMed ID: 29556721
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Importance of effective central nervous system therapy in isolated bone marrow relapse of childhood acute lymphoblastic leukemia. BFM (Berlin-Frankfurt-Münster) Relapse Study Group.
    Bührer C; Hartmann R; Fengler R; Schober S; Arlt I; Loewke M; Henze G
    Blood; 1994 Jun; 83(12):3468-72. PubMed ID: 8204875
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intensive treatment of children with acute lymphoblastic leukemia according to ALL-BFM-86 without cranial radiotherapy: results of Dutch Childhood Leukemia Study Group Protocol ALL-7 (1988-1991).
    Kamps WA; Bökkerink JP; Hählen K; Hermans J; Riehm H; Gadner H; Schrappe M; Slater R; van den Berg-de Ruiter E; Smets LA; de Vaan GA; Weening RS; van Weerden JF; van Wering ER; den der Does-van den Berg A
    Blood; 1999 Aug; 94(4):1226-36. PubMed ID: 10438710
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Outcomes of modified NHL-BFM-90 protocol for children and adolescents with lymphoblastic lymphoma].
    Sun X; Zhen Z; Zhu J; Wang J; Lu S; Xia Y; Sun F; Chen Y; Zhang F; Cai R; Li P; Guo X
    Zhonghua Xue Ye Xue Za Zhi; 2014 Dec; 35(12):1083-9. PubMed ID: 25543702
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinical features and prognosis of children with lymphoblastic lymphoma].
    Jin L; Zhang R; Huang S; Yang J; Duan YL; Zhang YH
    Zhonghua Zhong Liu Za Zhi; 2012 Feb; 34(2):138-42. PubMed ID: 22780934
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Allogeneic Hematopoietic Stem-Cell Transplantation Improves Disease-Free Survival Compared to Pediatric-Inspired Berlin-Frankfurt-Münster Chemotherapy in Adult Acute Lymphoblastic Leukemia.
    Aladag E; Aktimur SH; Aydın Ö; Demiroglu H; Buyukasik Y; Aksu S; Ozcebe OI; Haznedaroglu IC; Sayinalp N; Turgut M; Goker H
    Clin Lymphoma Myeloma Leuk; 2021 Mar; 21(3):147-153. PubMed ID: 33451957
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Allogeneic bone marrow transplantation for childhood acute lymphoblastic leukemia in second remission after intensive primary and relapse therapy according to the BFM- and CoALL-protocols: results of the German Cooperative Study.
    Dopfer R; Henze G; Bender-Götze C; Ebell W; Ehninger G; Friedrich W; Gadner H; Klingebiel T; Peters C; Riehm H
    Blood; 1991 Nov; 78(10):2780-4. PubMed ID: 1824271
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The long-term results of childhood acute lymphoblastic leukemia at two centers from Turkey: 15 years of experience with the ALL-BFM 95 protocol.
    Güneş AM; Oren H; Baytan B; Bengoa SY; Evim MS; Gözmen S; Tüfekçi O; Karapınar TH; Irken G
    Ann Hematol; 2014 Oct; 93(10):1677-84. PubMed ID: 24863691
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence, clinical pattern, and outcome of CNS involvement in childhood and adolescent non-Hodgkin's lymphoma differ by non-Hodgkin's lymphoma subtype: a Berlin-Frankfurt-Munster Group Report.
    Salzburg J; Burkhardt B; Zimmermann M; Wachowski O; Woessmann W; Oschlies I; Klapper W; Wacker HH; Ludwig WD; Niggli F; Mann G; Gadner H; Riehm H; Schrappe M; Reiter A
    J Clin Oncol; 2007 Sep; 25(25):3915-22. PubMed ID: 17761975
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Survival and prognostic analysis of T-cell lymphoblastic lymphoma patients treated with dose-adjusted BFM-90 regimen.
    Yu H; Mi L; Qi F; Wang X; Ye Y; Li M; Wang D; Ding N; Wang X; Song Y; Zhu J; Xie Y
    Aging (Albany NY); 2022 Apr; 14(7):3203-3215. PubMed ID: 35400665
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.